CN1747729A - Janus酪氨酸激酶3(JAK3)的选择性抑制方法 - Google Patents

Janus酪氨酸激酶3(JAK3)的选择性抑制方法 Download PDF

Info

Publication number
CN1747729A
CN1747729A CNA2003801054687A CN200380105468A CN1747729A CN 1747729 A CN1747729 A CN 1747729A CN A2003801054687 A CNA2003801054687 A CN A2003801054687A CN 200380105468 A CN200380105468 A CN 200380105468A CN 1747729 A CN1747729 A CN 1747729A
Authority
CN
China
Prior art keywords
cell
jak3
chemical compound
inhibition
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2003801054687A
Other languages
English (en)
Chinese (zh)
Inventor
罗伯特·A·柯肯
巴里·D·卡汉
斯坦尼斯瓦夫·M·斯特普科夫斯基
沃尔德马·普里贝
伊莎贝拉·福克特
希蒙·科辛斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The University of Texas System
Original Assignee
The University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University of Texas System filed Critical The University of Texas System
Publication of CN1747729A publication Critical patent/CN1747729A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/02—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C225/04—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated
    • C07C225/08—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and containing rings
    • C07C225/12—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and containing rings with doubly-bound oxygen atoms bound to carbon atoms being part of rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Surgery (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNA2003801054687A 2002-12-09 2003-12-09 Janus酪氨酸激酶3(JAK3)的选择性抑制方法 Pending CN1747729A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43185102P 2002-12-09 2002-12-09
US60/431,851 2002-12-09

Publications (1)

Publication Number Publication Date
CN1747729A true CN1747729A (zh) 2006-03-15

Family

ID=32507812

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2003801054687A Pending CN1747729A (zh) 2002-12-09 2003-12-09 Janus酪氨酸激酶3(JAK3)的选择性抑制方法

Country Status (17)

Country Link
US (2) US7365096B2 (cg-RX-API-DMAC7.html)
EP (1) EP1578411A4 (cg-RX-API-DMAC7.html)
JP (1) JP2006514021A (cg-RX-API-DMAC7.html)
KR (1) KR20050084224A (cg-RX-API-DMAC7.html)
CN (1) CN1747729A (cg-RX-API-DMAC7.html)
AU (1) AU2003297740B2 (cg-RX-API-DMAC7.html)
BR (1) BR0317099A (cg-RX-API-DMAC7.html)
CA (1) CA2506432A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP055843A (cg-RX-API-DMAC7.html)
HU (1) HUP0500844A2 (cg-RX-API-DMAC7.html)
MX (1) MXPA05006133A (cg-RX-API-DMAC7.html)
NO (1) NO20052497L (cg-RX-API-DMAC7.html)
NZ (1) NZ540427A (cg-RX-API-DMAC7.html)
PL (1) PL376844A1 (cg-RX-API-DMAC7.html)
RU (1) RU2005121672A (cg-RX-API-DMAC7.html)
WO (1) WO2004052359A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200504163B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104090115A (zh) * 2014-07-10 2014-10-08 上海益诺思生物技术有限公司 次级t细胞依赖抗体反应检测外源性化合物免疫抑制方法

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
JP4719671B2 (ja) 2003-03-28 2011-07-06 コーネル・リサーチ・ファンデーション・インコーポレイテッド ミグラスタチンアナログ組成物およびその使用
ES2421139T3 (es) 2003-07-30 2013-08-29 Rigel Pharmaceuticals, Inc. Compuestos de 2,4-pirimidindiamina para su uso en el tratamiento o la prevención de enfermedades autoinmunitarias
WO2005105146A1 (en) * 2004-05-03 2005-11-10 Novartis Ag Combinations comprising a s1p receptor agonist and a jak3 kinase inhibitor
US8957056B2 (en) 2004-05-25 2015-02-17 Sloan-Kettering Instiute For Cancer Research Migrastatin analogs in the treatment of cancer
US8188141B2 (en) 2004-09-23 2012-05-29 Sloan-Kettering Institute For Cancer Research Isomigrastatin analogs in the treatment of cancer
GB0507918D0 (en) 2005-04-19 2005-05-25 Novartis Ag Organic compounds
JP2008540436A (ja) * 2005-05-03 2008-11-20 ライジェル ファーマシューティカルズ, インコーポレイテッド Jakキナーゼインヒビターおよびそれらの使用
CA2963828A1 (en) 2005-10-26 2007-05-03 Novartis Ag Novel use of il-1beta compounds
PT2275103E (pt) 2005-11-21 2014-07-24 Novartis Ag Inibidores de mtor para o tratamento de tumores endócrinos
GB0601744D0 (en) 2006-01-27 2006-03-08 Novartis Ag Organic compounds
WO2008145664A1 (en) 2007-05-29 2008-12-04 Novartis Ag New indications for anti- il-i-beta therapy
JP2011515068A (ja) 2007-11-08 2011-05-19 ノバルティス アーゲー 慢性/硬化性同種移植腎症に対する遺伝子発現シグネチャー
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
CA2767616A1 (en) 2009-07-09 2011-01-13 The Scripps Research Institute Gene expression profiles associated with chronic allograft nephropathy
US8791100B2 (en) 2010-02-02 2014-07-29 Novartis Ag Aryl benzylamine compounds
UA112517C2 (uk) 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
US9018006B2 (en) 2010-07-23 2015-04-28 The University Of Toledo Stable Tregs and related materials and methods
EP2723740A1 (en) 2011-06-27 2014-04-30 Novartis AG Solid forms and salts of tetrahydro-pyrido-pyrimidine derivatives
ES2548414T3 (es) 2011-07-08 2015-10-16 Novartis Ag Novedosos derivados de pirrolo pirimidina
WO2013057711A1 (en) 2011-10-21 2013-04-25 Novartis Ag Quinazoline derivatives as pi3k modulators
US20140348848A1 (en) 2011-12-02 2014-11-27 Dhananjay Kaul Anti-il-1beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease
ES2661510T3 (es) 2011-12-15 2018-04-02 Novartis Ag Uso de inhibidores de la actividad o función de PI3K
IN2014CN04174A (cg-RX-API-DMAC7.html) 2011-12-22 2015-09-04 Novartis Ag
EP2794594A1 (en) 2011-12-22 2014-10-29 Novartis AG Quinoline derivatives
WO2013148638A2 (en) * 2012-03-26 2013-10-03 Ep Pharma, Inc. Compositions and methods related to inhibitors of jak kinase
TW201422625A (zh) 2012-11-26 2014-06-16 Novartis Ag 二氫-吡啶并-□衍生物之固體形式
WO2014128612A1 (en) 2013-02-20 2014-08-28 Novartis Ag Quinazolin-4-one derivatives
UY35675A (es) 2013-07-24 2015-02-27 Novartis Ag Derivados sustituidos de quinazolin-4-ona
KR20160060100A (ko) 2013-09-22 2016-05-27 칼리토르 사이언시즈, 엘엘씨 치환된 아미노피리미딘 화합물 및 이용 방법
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
KR20160145780A (ko) 2014-04-24 2016-12-20 노파르티스 아게 포스파티딜이노시톨 3-키나제 억제제로서의 아미노 피리딘 유도체
AU2014391610B2 (en) 2014-04-24 2018-01-25 Novartis Ag Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
CA2945212A1 (en) 2014-04-24 2015-10-29 Novartis Ag Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
US10443100B2 (en) 2014-05-22 2019-10-15 The Scripps Research Institute Gene expression profiles associated with sub-clinical kidney transplant rejection
EP3146077A4 (en) 2014-05-22 2018-05-02 The Scripps Research Institute Tissue molecular signatures of kidney transplant rejections
US11104951B2 (en) 2014-05-22 2021-08-31 The Scripps Research Institute Molecular signatures for distinguishing liver transplant rejections or injuries
EP3740468B1 (en) 2018-01-20 2025-12-31 Sunshine Lake Pharma Co., Ltd. Substituted Aminopyrimidine Compounds and Methods of Use
WO2020067887A1 (en) 2018-09-24 2020-04-02 Erasmus University Medical Center Rotterdam Specific inhibition of janus kinase 3 (jak3) for modulating anti-tumor immune responses
CN113840821A (zh) 2019-05-23 2021-12-24 诺华股份有限公司 Btk抑制剂的晶型

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA712187A (en) * 1965-06-22 J. C. Buisson Paul 2-(2'-oxo-1'-cyclododecyl) acetic acid, the salts thereof, and process of preparing same
FR1466205A (fr) * 1960-04-01 1967-01-20 Chimie Atomistique Acide 1-cétocyclododécyl-2-acétique, ses sels et leur procédé de préparation
AU566673B2 (en) * 1983-09-15 1987-10-29 F. Hoffmann-La Roche Ag Phenethylamine derivatives
US6136595A (en) * 1993-07-29 2000-10-24 St. Jude Children's Research Hospital Jak kinases and regulations of cytokine signal transduction
AU5682799A (en) * 1998-08-21 2000-03-14 Parker Hughes Institute Quinazoline derivatives
US6080747A (en) * 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
AU4903201A (en) * 1999-11-30 2001-07-03 Parker Hughes Institute Inhibitors of thrombin induced platelet aggregation
MY128449A (en) * 2000-05-24 2007-02-28 Sugen Inc Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
CA2326952A1 (en) 2000-11-27 2002-05-27 The Hospital For Sick Children T cell protein tyrosine phosphatase

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104090115A (zh) * 2014-07-10 2014-10-08 上海益诺思生物技术有限公司 次级t细胞依赖抗体反应检测外源性化合物免疫抑制方法
CN104090115B (zh) * 2014-07-10 2016-01-13 上海益诺思生物技术有限公司 次级t细胞依赖抗体反应检测外源性化合物免疫抑制方法

Also Published As

Publication number Publication date
US20050203177A1 (en) 2005-09-15
EP1578411A4 (en) 2007-05-02
US20080167220A1 (en) 2008-07-10
AU2003297740A2 (en) 2004-06-30
RU2005121672A (ru) 2005-11-20
US7928062B2 (en) 2011-04-19
EP1578411A1 (en) 2005-09-28
ZA200504163B (en) 2007-03-28
AU2003297740A1 (en) 2004-06-30
NO20052497D0 (no) 2005-05-24
US7365096B2 (en) 2008-04-29
ECSP055843A (es) 2005-11-22
BR0317099A (pt) 2005-10-25
KR20050084224A (ko) 2005-08-26
PL376844A1 (pl) 2006-01-09
WO2004052359A1 (en) 2004-06-24
AU2003297740B2 (en) 2008-09-11
CA2506432A1 (en) 2004-06-24
JP2006514021A (ja) 2006-04-27
HUP0500844A2 (en) 2007-08-28
MXPA05006133A (es) 2006-03-09
NO20052497L (no) 2005-09-02
NZ540427A (en) 2008-04-30

Similar Documents

Publication Publication Date Title
AU2003297740B2 (en) Methods for selectively inhibiting Janus tyrosine kinase 3 (Jak3)
US10245262B2 (en) Immunological reagents and uses therefor
CN1889958A (zh) 抑制免疫应答或治疗增生性疾病的方法
CN105188376A (zh) Malt1的小分子抑制剂
US11312676B2 (en) Small molecule stimulators of steroid receptor coactivator proteins and their use in the treatment of cancer
US20210283091A1 (en) Decreasing immune activity through modulation of postcellular signaling factors
US20140294870A1 (en) Autoimmune and Inflammatory Disorder Therapy
WO2022082306A1 (en) Use of n-myristoyl transferase (nmt) inhibitors in the treatment of cancer, autoimmune disorders, and inflammatory disorders
CN1094046A (zh) 取代的黄嘌呤衍生物
US12595227B2 (en) Compositions and methods for treatment of platinum-based chemotherapeutic resistant tumors
US20250122209A1 (en) Methods and compositions for drugs to treat ophthalmic diseases
Vafadari et al. Phosphospecific flow cytometry for pharmacodynamic drug monitoring: analysis of the JAK-STAT signaling pathway
US20080279866A1 (en) Induction of immunosuppression by inhibition of ATM
Jernberg‐Wiklund et al. Control of Apoptosis in Human Multiple Myeloma by Insulin‐like Growth Factor I (IGF‐I)
CN1658881A (zh) 抗炎组合物及其使用方法
US20160031957A1 (en) Inhibitors of the linear ubiquitin chain assembly complex (lubac) and related methods
US20260041653A1 (en) An hdac inhibitor for treating cancer with a modified stk11 activity or expression
EP3652535A1 (en) Identification and use of cytotoxic t lymphocyte (ctl) antigen-specific target cell killing enhancer agents
WO2008016118A1 (en) Agent targeting dopamine receptor and screening method therefor
CN1418111A (zh) 新型配体及其制备方法
Doelling et al. Carnosinylation of Cardiac Antigens Attenuates Immunogenic Responses and Improves Function in Failing Hearts
US9371265B2 (en) Compositions and methods related to inhibitors of JAK kinase
WO2026096891A1 (en) Methods for enhancing immunotherapy in the treatment of glioblastoma
EP3797781A1 (en) Use of ec-7072 and synergic compositions thereof in treatment of chronic lymphocytic leukemia
KR20230137078A (ko) 카테콜아민/adrb2 매개 간질환 치료제 스크리닝 방법

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20060315